Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 15/20 | 0.59 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.55 |
| ▸ | SELL | P14151 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26192723 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1SELLSELPACHE | |
| SCHEMBL22314236 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1SELLSELPACHE | |
| SCHEMBL25823940 | 0.85 | SLC5A2 (0.46) | SLC5A2SLC5A1SELLSELPACHE | |
| SCHEMBL22796845 | 0.82 | SLC5A2 (0.60) | SLC5A2SLC5A1SELLSELPACHE | |
| SCHEMBL22796963 | 0.82 | SLC5A2 (0.56) | SLC5A2SLC5A1SELLSELPACHE | |
| SCHEMBL673897 | 0.82 | SLC5A2 (0.55) | SLC5A2SLC5A1 | |
| SCHEMBL8583515 | 0.82 | SLC5A2 (0.64) | SLC5A2SLC5A1SELLSELPACHE | |
| SCHEMBL27767824 | 0.82 | SLC5A2 (0.64) | SLC5A2SLC5A1SELLSELPACHE | |
| SCHEMBL8588551 | 0.82 | SLC5A2 (0.64) | SLC5A2SLC5A1SELLSELPACHE | |
| SCHEMBL24332755 | 0.81 | SELP (0.54) | SLC5A2SLC5A1SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226309-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | Synthorx, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024137864-A1 | CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES | Synthorx, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230381335-A1 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | SYNTHORX INC (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230277627-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023122573-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122750-A1 | CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND CETUXIMAB | Synthorx, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022256534-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022076859-A1 | IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES | Synthorx, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076853-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220016252-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | Synthorx, Inc. (US) | 2022-01-20 | — | — | US | disclosed |
| WO-2021263026-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | Synthorx, Inc. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210338829-A1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-11-04 | — | — | US | disclosed |
| US-11077195-B2 | IL-2 conjugates and methods of use thereof | Synthorx, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2021050554-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210070827-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210046160-A1 | Immuno Oncology Combination Therapies With IL-2 Conjugates | Synthorx, Inc. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200330601-A1 | IL-2 Conjugates and Methods of Use Thereof | Synthorx, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2020163532-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | Synthorx, Inc. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200246467-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | SYNTHORX INC (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338829-A1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | IL2, CCR10, IL2RA | SLC5A2 3976/4885SLC5A1 3942/4885SELL 28/4885 |
| US-20210046160-A1 | Immuno Oncology Combination Therapies With IL-2 Conjugates | IL2, IL2RA, IL15 | SLC5A2 2182/4885SLC5A1 4572/4885SELL 87/4885 |
| US-20220016252-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | IL2, IL2RA, EGFR | SLC5A2 1078/4885SLC5A1 3749/4885SELL 146/4885 |
| US-20240226309-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | IL2, IL2RA, CD22 | SLC5A2 1213/4885SLC5A1 3884/4885SELL 50/4885 |
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | IL15, IL15RA, IL5 | SLC5A2 2523/4885SLC5A1 2021/4885SELL 27/4885 |
| US-11077195-B2 | IL-2 conjugates and methods of use thereof | IL2, IL2RA, IL15 | SLC5A2 859/4885SLC5A1 4126/4885SELL 35/4885 |
| US-20210070827-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | SLC5A2 555/4885SLC5A1 3284/4885SELL 46/4885 |
| US-20200246467-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, IL15 | SLC5A2 859/4885SLC5A1 4126/4885SELL 35/4885 |
| US-20230277627-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | IL2, IL2RA, PDCD1LG2 | SLC5A2 1050/4885SLC5A1 4375/4885SELL 104/4885 |
| US-20200330601-A1 | IL-2 Conjugates and Methods of Use Thereof | IL2, IL2RA, IL15 | SLC5A2 859/4885SLC5A1 4126/4885SELL 35/4885 |
| US-20230381335-A1 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | IL2, PDCD1LG2, CD274 | SLC5A2 3697/4885SLC5A1 4732/4885SELL 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.